Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Yale University |
---|---|
Information provided by: | Yale University |
ClinicalTrials.gov Identifier: | NCT00773422 |
The purpose of this stuy is to examine how medications thought to attenuate the effects of alcohol (naltrexone) and smoking cessation medications (varenicline) affect the ability to resist smoking and also subsequent ad-lib smoking, following a low-dose alcohol priming drink, in non-treatment seeking alcohol-drinking daily smokers.
Condition | Intervention | Phase |
---|---|---|
Smoking |
Drug: naltrexone Drug: varenicline Drug: placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Factorial Assignment |
Official Title: | The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse |
Estimated Enrollment: | 60 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | August 2010 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
naltrexone + varenicline: Experimental
naltrexone (25mg) + varenicline (2mg)
|
Drug: naltrexone
25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
Drug: varenicline
2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
|
varenicline: Experimental
varenicline 2mg
|
Drug: varenicline
2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
|
placebo: Placebo Comparator
placebo control
|
Drug: placebo
placebo
|
Ages Eligible for Study: | 21 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sabrina Coppola | 203-737-2827 |
United States, Connecticut | |
Yale Center for Clinical Investigation, Yale University | Recruiting |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Sherry A McKee, PhD | Yale University |
Responsible Party: | Yale University School of Medicine ( Sherry McKee ) |
Study ID Numbers: | HIC0710003188, P50AA15632 |
Study First Received: | October 14, 2008 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00773422 |
Health Authority: | United States: Institutional Review Board |
smoking lapse behavior smoking cessation varenicline naltrexone medication effect on smoking lapse behavior |
Smoking Naltrexone Ethanol |
Habits Sensory System Agents Therapeutic Uses Physiological Effects of Drugs |
Narcotic Antagonists Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |